Chart, page-2076

First 2076 Last

Share
Profile

Follow
kasta1

662 Posts.

124

14/09/20

18:45

Post #: 47332268
Share

Originally posted by YLJ: ↑

I think that is super important to know.
A good chartist sees all the different messages (often conflicting one's) and
has to make a call about what to go with, or to sit on the sidelines. To point out
only one side of the picture is (although apparently a popular approach) is not faithful
to the essence of TA (or honest, IMO).
Pure technical analysis at its core is meant to be as unbiased as possible. One has to
have a trading methodology and make a judgment call. Usually, the more that is left to
a repeatable process that can stand the test of time, the better.
It is to find the highest probability scenarios that provide minimal risk and maximum
reward. Many (though not all) of history's (and today's) best traders traded things they
knew almost nothing (or minimally) about. For them, it was never about any one company,
but rather the sum of all the trades they take. It is clear that many do not understand that.
So much of the basic accepted principles of trading (including patterns) are easily
researched (from reputable resources and classic works) that it is sad that people do not
bother to verify what they come across.
When one begins to integrate Fundemental Analysis and outside bias into charting, it is very
hard not to become blind to some of the chart indications that may appear. This can
turn out good or bad. Charting, as I have said many times, is not a prophecy.
There is nothing wrong with that approach when it is level-headed. Some succeed immensely
with it, and some do themselves more harm than good in the long run. Many who invest on
fundamentals are best not looking at charts at all (or short term price movement). Many of the
best do not. If they are confident enough it should not matter what the chart may indicate as
it can be, and is often enough wrong. If they are not confident enough it will either give them
false confidence or put them through emotional hell, and if that is the case, they best
reconsider the basis for their "investment".
I personally have an affinity for charting in its purest form and I will always at attempt to
provide that perspective, as I see it.

Expand

Appreciate your posts Y, fir their content.
But our of curiosity do you look at yourself in the mirror a lot.

BRN Price at posting: 67.0¢ Sentiment: Buy Disclosure: Not Held
3 Upvote

0 Great analysis

Reply

Top Stories

COB

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

OJC

SPC to merge with Original Juice Co and Nature One Dairy

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

There are more pages in this discussion • 18,831 more messages in this thread...

First 2076 Last

Add BRN (ASX) to my watchlist

(20min delay)
Last 25.5¢		Change 0.020(8.51%)		Mkt cap ! $500.4M

Open	High	Low	Value	Volume
22.5¢	27.5¢	22.0¢	$8.399M	33.52M

Buyers (Bids)

No.	Vol.	Price($)
6	338805	25.5¢

Sellers (Offers)

Price($)	Vol.	No.
26.0¢	10000	1

View Market Depth

No.	Vol.	Price($)
6	338805	0.255
15	429045	0.250
13	731308	0.245
9	88244	0.240
6	93087	0.235

Price($)	Vol.	No.
0.260	10000	1
0.265	231580	5
0.270	636408	10
0.275	501185	11
0.280	1156121	31

Last trade - 16.10pm 02/10/2024 (20 minute delay)

BRN (ASX) Chart

Chart, page-2076

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

SPC to merge with Original Juice Co and Nature One Dairy

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Chart, page-2076

Top Stories

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

SPC to merge with Original Juice Co and Nature One Dairy

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News